Evidence map›Paper›PMID 27695349›Full record

ReviewOncoTargets and therapy2016

Proton beam therapy: clinical utility and current status in prostate cancer.

Kosj Yamoah, Peter As Johnstone

Open access · goldAbstract readReview
In one paragraph

Review in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Radiation and Thyroid Cancer.International journal of molecular sciences · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Kosj YamoahRadiation Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Peter As JohnstoneRadiation Oncology Department, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Moffitt Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proton beam therapy has recently become available to a broader population base. There remains much controversy about its routine use in prostate cancer. We provide an analysis of the existing literature regarding efficacy and toxicity of the technique. Currently, the use of proton beam therapy for prostate cancer is largely dependent on continued reimbursement for the practice. While there are potential benefits supporting the use of protons in prostate cancer, the low risk of toxicity using existing techniques and the high cost of protons contribute to lower the value of the technique.

Indexed as

prostate cancerproton therapyradiotherapy

Identifiers

PMID27695349
PMCPMC5033502
OpenAlexW2520954479

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.